- Home
- WEA vs AGEN Comparison
WEA vs AGEN Comparison
Compare WEA & AGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WEA
- AGEN
- Stock Information
- Founded
- WEA 2002
- AGEN 1994
- Country
- WEA United States
- AGEN United States
- Employees
- WEA N/A
- AGEN N/A
- Industry
- WEA Trusts Except Educational Religious and Charitable
- AGEN Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- WEA Finance
- AGEN Health Care
- Exchange
- WEA Nasdaq
- AGEN Nasdaq
- Market Cap
- WEA 129.0M
- AGEN 105.3M
- IPO Year
- WEA N/A
- AGEN 2000
- Fundamental
- Price
- WEA $10.76
- AGEN $3.43
- Analyst Decision
- WEA
- AGEN Buy
- Analyst Count
- WEA 0
- AGEN 4
- Target Price
- WEA N/A
- AGEN $8.33
- AVG Volume (30 Days)
- WEA 46.1K
- AGEN 802.0K
- Earning Date
- WEA 01-01-0001
- AGEN 05-12-2025
- Dividend Yield
- WEA 7.87%
- AGEN N/A
- EPS Growth
- WEA N/A
- AGEN N/A
- EPS
- WEA N/A
- AGEN N/A
- Revenue
- WEA N/A
- AGEN $99,524,000.00
- Revenue This Year
- WEA N/A
- AGEN $14.49
- Revenue Next Year
- WEA N/A
- AGEN N/A
- P/E Ratio
- WEA N/A
- AGEN N/A
- Revenue Growth
- WEA N/A
- AGEN N/A
- 52 Week Low
- WEA $9.60
- AGEN $1.38
- 52 Week High
- WEA $11.29
- AGEN $19.69
- Technical
- Relative Strength Index (RSI)
- WEA 54.55
- AGEN 55.31
- Support Level
- WEA $10.56
- AGEN $2.95
- Resistance Level
- WEA $10.71
- AGEN $3.90
- Average True Range (ATR)
- WEA 0.13
- AGEN 0.40
- MACD
- WEA 0.01
- AGEN -0.07
- Stochastic Oscillator
- WEA 96.67
- AGEN 43.24
About WEA Western Asset Bond Fund Share of Beneficial Interest
Western Asset Premier Bond Fund is a diversified closed-end management investment company. Its investment objective is to provide current income and capital appreciation by investing in a diversified portfolio of investment-grade bonds. The Fund invests in sectors, such as financials, energy, telecommunication services, consumer discretionary, healthcare, materials, information technology, and consumer staples.
About AGEN Agenus Inc.
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).